What's Happening?
On World Diabetes Day 2026, the World Health Organization (WHO) released its inaugural guidelines for the diagnosis and management of type 1 diabetes in adults. These guidelines provide evidence-based recommendations applicable across various settings,
including those with limited resources, emergencies, and humanitarian crises. Type 1 diabetes is a chronic condition where the body fails to produce sufficient insulin, necessitating daily insulin dependence for survival. Despite insulin's discovery over a century ago, many individuals with type 1 diabetes still lack access to affordable and high-quality insulin and necessary care. In 2025, approximately 9.5 million people globally lived with type 1 diabetes, with an additional 500,000 diagnoses made that year. While often associated with childhood, the condition is increasingly affecting adults. Dr. Søren Brostrøm, WHO Director of Noncommunicable Diseases and Mental Health, emphasized that these new guidelines aim to assist countries in delivering optimal care, particularly where health services are disrupted or resources are scarce. The guidelines recommend multiple daily insulin injections, with doses adjusted based on blood glucose levels, and endorse human insulin as an effective option. Regular blood glucose monitoring, either through clinic tests or home-based methods like finger-prick tests or continuous glucose monitors, is also advised. In situations where blood glucose testing is unavailable, urine glucose testing can be considered.
Why It's Important?
These new WHO guidelines are crucial for standardizing and improving care for adults with type 1 diabetes globally, especially in underserved regions. The emphasis on accessibility to affordable insulin and self-monitoring tools directly addresses a significant global health inequity. With 9.5 million people living with type 1 diabetes in 2025 and a growing number of adult diagnoses, these guidelines provide a framework for healthcare systems worldwide to enhance their response to this chronic condition. The recommendations for insulin administration and glucose monitoring are vital for preventing severe complications such as blindness, kidney failure, heart attacks, stroke, and amputations, which are common consequences of poorly managed diabetes. By offering guidance for low-resource and emergency settings, the WHO aims to ensure that even vulnerable populations receive essential care, thereby reducing morbidity and mortality associated with type 1 diabetes. The initiative also supports the broader WHO goal of ensuring universal access to affordable insulin and blood glucose self-monitoring by 2030, highlighting a commitment to global health equity and improved patient outcomes.
What's Next?
The WHO plans to support countries in implementing these new guidelines by providing practical tools and guidance to track progress. This will involve assisting national health authorities in integrating the recommendations into their healthcare systems and monitoring their effectiveness. Countries are also encouraged to actively involve individuals living with type 1 diabetes in the design, implementation, and evaluation of diabetes programs. This participatory approach aims to ensure that interventions are patient-centered and address the real-world needs of those affected by the condition. The 2026 World Diabetes Day theme, 'Early action on diabetes,' underscores the ongoing global effort to raise awareness and promote timely interventions. The WHO will continue its efforts to achieve its targets of ensuring access to affordable insulin treatment and blood glucose self-monitoring for all people with type 1 diabetes by 2030. This will likely involve continued advocacy, resource mobilization, and technical support to member states to strengthen their diabetes care infrastructure and policies.
Beyond the Headlines
The issuance of these guidelines reflects a broader recognition of the evolving epidemiology of type 1 diabetes, particularly its increasing prevalence in adults, challenging the traditional perception of it as solely a childhood disease. This shift necessitates a re-evaluation of public health strategies and healthcare provider training to adequately address the needs of adult patients. Furthermore, the guidelines highlight the persistent global challenge of equitable access to essential medicines like insulin, even a century after its discovery. This underscores systemic issues in pharmaceutical supply chains, pricing, and healthcare infrastructure, particularly in low-income settings. The WHO's emphasis on self-management and patient involvement also signals a move towards more patient-centric care models, empowering individuals to play a more active role in managing their chronic conditions. This approach could foster greater health literacy and self-efficacy among patients, potentially leading to better long-term health outcomes and reduced healthcare burdens. The guidelines also implicitly call for increased investment in diabetes research and development, especially for solutions tailored to resource-limited environments.













